Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gemini Therapeutics Inc (GMTX)

Gemini Therapeutics Inc (GMTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,789
  • Shares Outstanding, K 43,227
  • Annual Sales, $ 0 K
  • Annual Income, $ -71,870 K
  • 60-Month Beta 0.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.52
Trade GMTX with:

Options Overview Details

View History
  • Implied Volatility 330.78% ( +103.19%)
  • Historical Volatility 71.46%
  • IV Percentile 83%
  • IV Rank 40.16%
  • IV High 792.93% on 05/09/22
  • IV Low 20.59% on 02/14/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 4
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,485
  • Open Int (30-Day) 1,534

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +47.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +4.10%
on 05/24/22
1.6900 -24.85%
on 05/03/22
-0.2200 (-14.77%)
since 04/22/22
3-Month
1.1600 +9.48%
on 03/01/22
1.8400 -30.98%
on 04/14/22
-0.1900 (-13.01%)
since 02/24/22
52-Week
1.1600 +9.48%
on 03/01/22
12.9500 -90.19%
on 06/02/21
-9.6700 (-88.39%)
since 05/24/21

Most Recent Stories

More News
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.

NERV : 0.3505 (-2.64%)
CRBP : 0.3108 (-1.02%)
ALVR : 3.89 (-2.75%)
GMTX : 1.2700 (-6.62%)
Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

GMTX : 1.2700 (-6.62%)
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

NERV : 0.3505 (-2.64%)
CRBP : 0.3108 (-1.02%)
CTXR : 0.9671 (+7.32%)
GMTX : 1.2700 (-6.62%)
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections

AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.

NERV : 0.3505 (-2.64%)
CRBP : 0.3108 (-1.02%)
ALVR : 3.89 (-2.75%)
GMTX : 1.2700 (-6.62%)
Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder

The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.

CPRX : 6.87 (-0.72%)
NERV : 0.3505 (-2.64%)
MRNS : 5.01 (-8.41%)
GMTX : 1.2700 (-6.62%)
Gemini Therapeutics Provides Corporate Update

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate...

GMTX : 1.2700 (-6.62%)
Gemini Therapeutics Provides GEM103 Program Update

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates...

GMTX : 1.2700 (-6.62%)
Gemini Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD) today reported its...

GMTX : 1.2700 (-6.62%)
Gemini Therapeutics Announces Poster Presentation at AAO 2021

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that...

GMTX : 1.2700 (-6.62%)
Gemini Therapeutics to Participate in Upcoming Investor Conferences

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that...

GMTX : 1.2700 (-6.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Gemini Therapeutics Inc. is a clinical stage precision medicine company. It engages in developing novel therapeutic compounds to treat genetically defined age-related macular degeneration. The company's lead candidate principally includes GEM103. Its pipeline includes recombinant proteins, gene therapies...

See More

Key Turning Points

3rd Resistance Point 1.5033
2nd Resistance Point 1.4367
1st Resistance Point 1.3533
Last Price 1.2700
1st Support Level 1.2033
2nd Support Level 1.1367
3rd Support Level 1.0533

See More

52-Week High 12.9500
Fibonacci 61.8% 8.4462
Fibonacci 50% 7.0550
Fibonacci 38.2% 5.6638
Last Price 1.2700
52-Week Low 1.1600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar